Global Chronic Myeloid Leukemia (CML) Market Report 2017: Focus on Forecasts, Treatment, Epidemiology, Marketed Drugs & Pipeline
DUBLIN, Feb. 16, 2018 /PRNewswire/ --
The "Chronic Myeloid Leukemia (CML)" report has been added to ResearchAndMarkets.com's offering.
http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a myeloproliferative disorder characterized by a single cytogenetic hallmark: the chromosomal translocation t(9;22)(q34;q11), known as the Philadelphia (Ph) chromosome. In a small minority of patients who exhibit the characteristics of CML, the Ph chromosome cannot be detected - this is referred to as Ph-negative CML, or atypical CML.
Market Snapshot
-- The CML market will experience a short period of growth followed by a decline in sales due to the onset of generic competition. -- The largest unmet needs in CML are overcoming TKI resistance and addressing patients with accelerated or blast phase disease. -- The number of incident chronic myeloid leukemia cases is expected to increase by 25% over the next 20 years. -- Generic imatinib will dominate first-line treatment as Sprycel and Tasigna compete for market share in the second line. -- Asciminib is currently the primary candidate in the pipeline, and may benefit patients progressing on available TKIs.
Key Topics Covered:
Forecast: Chronic Myeloid Leukemia
-- Executive Summary -- Market Overview And Trends -- Market Definition And Methodology -- Asciminib -- Bosulif (Bosutinib) -- Gleevec (Imatinib) -- Iclusig (Ponatinib) -- Sprycel (Dasatinib) -- Synribo (Omacetaxine Mepesuccinate) -- Tasigna (Nilotinib) -- Primary Research Methodology
Treatment: Chronic Myeloid Leukemia
-- Executive Summary -- Primary Research Methodology -- Disease Definition And Diagnosis -- Patient Segmentation -- Current Treatment Options -- Prescribing Trends
Epidemiology: Chronic Myeloid Leukemia In The Us, Japan, And 5EU
-- Executive Summary -- Disease Background -- Sources And Methodology -- Forecast -- Epidemiologist Insight -- Strengths And Limitations -- Bibliography -- Appendix: Additional Sources
Marketed Drugs: Chronic Myeloid Leukemia
-- Executive Summary -- Product Overview -- Product Profile: Bosulif -- Product Profile: Gleevec -- Product Profile: Iclusig -- Product Profile: Sprycel -- Product Profile: Synribo -- Product Profile: Tasigna
Pipeline: Chronic Myeloid Leukemia
-- Executive Summary -- Clinical Pipeline Overview -- Comparator Therapy -- Product Profile (Late Stage): Asciminib
For more information about this report visit https://www.researchandmarkets.com/research/k7kr9g/global_chronic?w=5
Media Contact:
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
View original content:http://www.prnewswire.com/news-releases/global-chronic-myeloid-leukemia-cml-market-report-2017-focus-on-forecasts-treatment-epidemiology-marketed-drugs--pipeline-300600012.html
SOURCE Research and Markets